NCT00338416View on ClinicalTrials.gov

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

January 31, 2005

Conditions
CancerAnemia
Interventions
DRUG

Epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00338416 - An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks | Biotech Hunter | Biotech Hunter